Investigating the health-economic profiles of biomarker-driven immunosuppresion (BIO-DrIM) following solid organ transplantation
Vol 1, Issue 1, 2016, Article identifier:48-65
VIEWS - 773 (Abstract) 431 (PDF)
Abstract
Keywords
Full Text:
PDFReferences
Abboudi H and MacPhee I A M, 2012, Individualized immunosuppression in transplant patients: potential role of pharmacogenetics. Pharmacogenomics and Personalized Medicine, vol.5: 63–72.
Olbricht C J, 2012, Why do we need biomarkers in solid organ transplantation. Clinica Chimica Acta, 1310–1311.
Baron D, Giral M and Brouard S, 2015, Reconsidering the detection of tolerance to individualize immunosuppression minimization and to improve long-term kidney graft outcomes. Transplant International, vol.28: 938–959.
Woodroffe R, Yao G L, Meads C, et al. 2005, Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technology Assessment, vol.9(21).
Haller M and Oberbauer R, 2008, Calcineurin inhibitor minimization, withdrawal and avoidance protocols after kidney transplantation. Transplant International, vol.22: 69–77.
Hernadez-Fuentes M P and Lechler R I, 2010, A ‘bio-marker signature’ for tolerance in transplantation. Nature Reviews Nephrology, vol.6: 606–613.
Lerut J and Sanchez-Fueyo A, 2006, An appraisal of tolerance in liver transplantation. American Journal of Transplantation, vol.6: 1774–1780.
Babel N, Reinke P and Volk H-D, 2009, Lymphocyte markers and prediction of long-term renal allograft acceptance. Current Opinion in Nephrology and Hyper-tension, vol.18: 489–494.
Bestard O, Cruzado J M, Ia Franquesa M, et al. 2010, Biomarkers in renal transplantation. Current Opinion in Organ Transplantation, vol.15: 467–473.
Goodacre S and Thokala P, 2015, The economics of cardiac biomarker testing in suspected myocardial infarction. Clinical Biochemistry, vol.48: 213–217.
Bestard O, Cruzado J M, Lucia M, et al. 2013, Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation. Kidney International, vol.84: 1226–1236.
McEwan P, Dixon S, Baboolal K, et al. 2006, Evaluation of the cost-effectiveness of sirolimus versus tac-rolimus for immunosuppression following renal trans-plantation in the UK. Pharmacoeconomics, vol.24(1): 67–79.
Jürgensen J S, Arns W and Hass B, 2010, Cost-effectiveness of immunosuppressive regimens in renal trans-plant recipients in Germany: a model approach. European Journal of Health Economics, vol.11: 15–25.
Muduma G, Shaw J, Hart W M, et al. 2014, Cost utility analysis of immunosuppressive regimens in adult renal transplant recipients in England and Wales. Patient Preference and Adherence, vol.8: 1537–1546.
Hall P S and McGabe C, 2013, What evidence is there for the reimbursement of personalised medicine? Pharmacoeconomics, vol.31: 181–183.
Ijzerman M J and Steuten L M G, 2011, Early assessment of medical technologies to inform product development and market access — a review of methods and applications. Applied Health Economics & Health Pol-icy, vol. 9(5): 331–347.
Backhouse M E, Wonder M, Hornby A, et al. 2011, Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study. Value in Health, vol.14: 608–615.
Drummond M, Tarricone R and Torbica A, 2013, Assessing the added value of health technologies: recon-ciling different perspectives. Value in Health, vol.16: S7–S13.
Sculpher M and Claxton K, 2010, Sins of omission and obfuscation: IQWiG`s guidelines on economic evaluation. Health Economics, vol.19: 1132–1136.
Cohen D J and Rexnolds M R, 2008, Interpreting the results of cost-effectiveness studies. Journal of the American College of Cardiology, vol.52(25): 2119–2126.
Chuang L-H and Whitehead S J, 2011, Mapping for economic evaluation. British Medical Bulletin, vol.101: 1–15.
Laupacis A, Pus N, Muirhead N, et al. 1993, Dis-ease-specific questionnaire for patients with a renal transplant. Nephron, vol.64: 226–231.
Rebollo P, Ortega F, Ortega T, et al. 2003, Spanish validation of the “Kidney Transplant Questionnaire”: a useful instrument for assessing health-related quality of life in kidney transplant patients. Health and Quality of Life Outcomes, vol.1: 56.
Rostami Z, Tavallaii S A, Jahani Y, et al. 2011, Assessment of quality of life in a single-center transplantation population using the Kidney Transplant Questionnaire-25 questionnaire. Transplantation Proceedings, vol.43: 590–591.
Chisholm-Burns M A, Erickson S R, Spivey C A et al. 2011, Concurrent validity of kidney transplant questionnaire in US renal transplant recipients. Patient Preference and Adherence, vol.5: 517–522.
Ramsey S, Willke R, Glick H, et al. 2015, Cost-effectiveness analysis alongside clinical trials II — an ISPOR good research practices task force report. Value in Health, vol.18: 161–172.
Husereau D, Drummond M, Petrou S, et al. 2013, Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMC Medicine, vol.11: 80.
Petrou S and Gray A, 2011, Economic evaluation along-side randomized controlled trials: design, conduct, analysis, and reporting. British Medical Journal, vol.342: d1548.
Fiebiger W, Mitterbauer C and Oberbauer R, 2004, Health-related quality of life outcomes after kidney trans-plantation. Health and Quality of Life Outcomes, vol.2: 2.
Xu X, Nardini H K G and Ruger J P, 2014, Micro-costing studies in the health and medical literature: protocol for a systematic review. Systematic Reviews, vol.3(47).
Abou-El-Enein M, Römhild A, Kaiser D, et al. 2013, Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs. Cytotherapy, vol.15: 362–383.
Fitzgerald P, Goodacre S W, Cross E, et al. 2011, Cost- effectiveness of point-of-care biomarker assessment for suspected myocardial infarction: the Randomized Assessment of Treatment Using Panel Assay of Cardiac markers (RATPAC) trial. Society for Academic Emergency Medicine, vol.18(5): 488–495.
O`Sullivan A K, Thompson D and Drummond M, 2005, Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations? Value in Health, vol.8(1): 67–79.
Dziura J D, Post L A, Zhao Q, et al. 2013, Strategies for dealing with missing data in clinical trials: from design to analysis. Yale Journal of Biology and Medicine, vol.86: 343–358.
Miners A, 2008, Estimating costs for cost-effectiveness analysis. Pharmacoeconomics, vol.26(9): 745–751.
Institute for Quality and Efficiency in Health Care (IQWiG), 2009, Working paper — cost estimation, ver-sion 1.0, accessed March 5, 2015,
Shi L, Hodges M, Drummond M, et al. 2010, Good re-search practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the IS-POR drug cost task force report — part VI. Value in Health, vol.13: 28–33.
The University of York — Centre for Health Economics, 2015, NICE Threshold Press release, accessed February 21, 2015,
Kasiske B L, Zeier G M, Chapman J R, et al. 2010, KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney International, vol.77: 299–311.
Baker R, Jardine A and Andrews P, 2011, Post-operative care of the kidney transplant recipient, 5th edition Final Version, The Renal Association, accessed February 5, 2011,
Rivero-Arias O and Gray A, 2010, The multinational nature of cost-effectiveness analyses alongside multina-tional clinical trials. Value in Health, vol.13(1): 34–41.
DOI: http://dx.doi.org/10.18063/APM.2016.01.004
(773 Abstract Views, 431 PDF Downloads)
Refbacks
- There are currently no refbacks.
Copyright (c) 2016 Simon A Weber, Malte Pietzsch, Oriol Bestard, Josep M Grinyo, Ondrej Viklicky, Petra Reinke

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
| Advances in Precision Medicine is a peer-reviewed, open-access journal. All journal content, except where otherwise noted, is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |